Study flow
ulcer
SECONDARY, ULCER
In this study, 92 patients were screened and considered eligible between December 2, 2020, and November 03, 2021. Among them, 46 individuals were randomly assigned to the control group, whereas the other 46 individuals were assigned to the experimental group. Overall, 81 (88.0%) of 92 patients completed the whole process and were included in the efficacy analysis, while the remaining 11 (12.0%) patients were lost to follow-up and discontinued the study. All 92 individuals were included in the safety analysis (Fig. Trial profile. The primary outcome (the healing rate) and secondary outcomes (ulcer area 14 days later, absolute change of ulcer area, and the wound characteristics in endoscopic re-evaluation 14 days after ESD) were assessed in the population completing the whole process. The safety analyses were measured among all the patients who were randomly assigned and completed the oesophageal ESD. ESD, endoscopic submucosal dissection.